1,909 Shares in Zoetis Inc. (NYSE:ZTS) Acquired by Warm Springs Advisors Inc.

Warm Springs Advisors Inc. bought a new stake in Zoetis Inc. (NYSE:ZTS) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 1,909 shares of the company’s stock, valued at approximately $311,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ZTS. Vanguard Group Inc. grew its stake in shares of Zoetis by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company’s stock valued at $6,739,905,000 after buying an additional 120,158 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Zoetis by 1.8% during the 4th quarter. Geode Capital Management LLC now owns 10,617,897 shares of the company’s stock valued at $1,726,075,000 after acquiring an additional 190,137 shares during the period. Polen Capital Management LLC grew its position in Zoetis by 17.5% in the 4th quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company’s stock valued at $1,219,237,000 after acquiring an additional 1,116,541 shares in the last quarter. Wellington Management Group LLP increased its stake in Zoetis by 78.5% during the fourth quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company’s stock worth $1,133,755,000 after purchasing an additional 3,059,255 shares during the period. Finally, Northern Trust Corp increased its stake in Zoetis by 13.3% during the fourth quarter. Northern Trust Corp now owns 6,426,394 shares of the company’s stock worth $1,047,052,000 after purchasing an additional 755,893 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insider Transactions at Zoetis

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares in the company, valued at $1,868,244.30. This represents a 9.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the transaction, the executive vice president now directly owns 15,781 shares in the company, valued at approximately $2,682,770. The trade was a 2.02% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.18% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $162.92 on Friday. The company has a market cap of $72.53 billion, a P/E ratio of 29.78, a PEG ratio of 2.78 and a beta of 0.94. The firm has a fifty day moving average price of $156.48 and a 200 day moving average price of $164.88. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. During the same period in the previous year, the business earned $1.38 EPS. Zoetis’s revenue for the quarter was up 1.4% on a year-over-year basis. Sell-side analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a yield of 1.23%. Zoetis’s payout ratio is currently 35.91%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Stifel Nicolaus dropped their price objective on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a report on Monday, April 14th. UBS Group decreased their price target on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, May 7th. Barclays boosted their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Piper Sandler increased their price objective on Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a research note on Monday, May 12th. Finally, Morgan Stanley decreased their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $212.75.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.